ATR Kinase Inhibitors: Parameter Changes for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ATR inhibitors for cancer treatment are not sufficiently effective, necessitating the development of improved pharmaceutics with inhibitory activity against ATR protein kinase.
Innovation Solution
Development of novel compounds, including stereoisomers, pharmaceutically acceptable salts, and prodrugs, specifically designed to inhibit ATR protein kinase, which are administered to treat various diseases such as cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current ATR inhibitors are used for cancer treatment, then some inhibitory activity is achieved, but the treatment effectiveness is insufficient
Solution Approach 1:
The patent applies parameter changes by systematically varying key molecular parameters of the ATR inhibitor compounds, including substituting different heteroatoms (N, O, S) at specific positions (Z1-Z4), modifying ring structures (Ring A and Ring B), and adjusting substituent groups (R1-R3, Ra-Rc). These parameter variations optimize the compounds' binding affinity to ATR kinase and improve their inhibitory potency, directly addressing the insufficient treatment effectiveness of current inhibitors
Solution Approach 2:
The patent employs composite material principles by creating complex multi-component molecular structures that combine various heterocyclic rings, aromatic systems, and functional groups into unified inhibitor compounds. The composite nature of these molecules, featuring multiple rings (Ring A, Ring B), heteroatoms, and substituent groups working together, enables enhanced specificity and potency against ATR kinase compared to simpler inhibitor structures
2Reliability
If novel compounds with improved structure are developed, then inhibitory activity against ATR is enhanced, but the complexity of compound design increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a core heterocyclic structure containing Z1-Z4 positions, Ring A and Ring B moieties, and various substituent groups (R1-R3, Ra-Rc). This segmented approach allows independent optimization of each segment's contribution to ATR binding, enabling systematic structure-activity relationship studies while managing molecular complexity through modular design
Solution Approach 2:
The patent implements universality by designing a versatile core molecular framework that can accommodate multiple types of substituents and ring variations while maintaining ATR inhibitory activity. The standardized Z1-Z4 positioning system and consistent ring attachment points create a universal scaffold that can be systematically modified with different functional groups to optimize activity without requiring entirely new molecular designs for each variant
Data Source
AI summary
The present disclosure relates to novel compounds useful as inhibitors of ATR kinase, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.